Evommune, Inc. (EVMN): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$80.47M

Year ended 2025-12-31

-$101.29M

Trailing 12 months to 2026-06-30

2024-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$80.47M	n/m	2026-03-05, From 2025-01-01
2024-12-31	-$69.51M	n/a	2026-03-05, From 2024-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Evommune, Inc. (EVMN)	2025-12-31	-$80.47M	n/m
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	-$123.80M	n/m
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$270.0K	n/m
CV Sciences, Inc. (CVSI)	2025-12-31	-$278.0K	n/m
Pyxis Oncology, Inc. (PYXS)	2025-12-31	-$79.91M	n/m
Prelude Therapeutics Inc (PRLD)	2025-12-31	-$102.86M	n/m
Jaguar Health, Inc. (JAGX)	2025-12-31	-$43.99M	n/m
uniQure N.V. (QURE)	2025-12-31	-$170.59M	n/m
Precigen, Inc. (PGEN)	2025-12-31	-$107.31M	n/m

Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗